PALOPEGTERIPARATIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for palopegteriparatide and what is the scope of patent protection?
Palopegteriparatide
is the generic ingredient in one branded drug marketed by Ascendis Pharma Bone and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Palopegteriparatide has ninety-eight patent family members in twenty-seven countries.
One supplier is listed for this compound.
Summary for PALOPEGTERIPARATIDE
| International Patents: | 98 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in PALOPEGTERIPARATIDE? | PALOPEGTERIPARATIDE excipients list |
| DailyMed Link: | PALOPEGTERIPARATIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PALOPEGTERIPARATIDE
Generic Entry Date for PALOPEGTERIPARATIDE*:
Constraining patent/regulatory exclusivity:
TREATMENT OF HYPOPARATHYROIDISM IN ADULTS Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for PALOPEGTERIPARATIDE
| Drug Class | Parathyroid Hormone Analog |
Anatomical Therapeutic Chemical (ATC) Classes for PALOPEGTERIPARATIDE
US Patents and Regulatory Information for PALOPEGTERIPARATIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-003 | Aug 9, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-001 | Aug 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-001 | Aug 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-002 | Aug 9, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-001 | Aug 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-001 | Aug 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-003 | Aug 9, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PALOPEGTERIPARATIDE
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Slovenia | 3518961 | ⤷ Sign Up | |
| Poland | 3518961 | ⤷ Sign Up | |
| Japan | 7197468 | ⤷ Sign Up | |
| Japan | 2019535648 | 制御放出ＰＴＨ化合物の投薬レジメン | ⤷ Sign Up |
| Russian Federation | 2018143571 | ПРОЛЕКАРСТВО, СОДЕРЖАЩЕЕ САМОРАСЩЕПЛЯЕМЫЙ ЛИНКЕР | ⤷ Sign Up |
| Hungary | E062009 | ⤷ Sign Up | |
| Brazil | 112019005533 | regime de dosagem para um composto de pth de liberação controlada | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
